Clinical Scorecard: The Role of Inflammation in Early Risk Assessment Following Myocardial Infarction

At a Glance

Key Highlights

• INFLAME-MI score integrates inflammatory biomarkers and routine clinical parameters to predict in-hospital mortality after myocardial infarction.
• INFLAME-MI shows good calibration and clinical utility, especially in low-to-intermediate risk ACS patients not requiring immediate revascularization.
• Current GRACE scores, while comprehensive, may overestimate risk and have limited utility in guiding early invasive management.

Guideline-Based Recommendations

Diagnosis

• Use of inflammatory biomarkers such as neutrophil count, neutrophil to lymphocyte ratio, and C-reactive protein to refine risk stratification after ACS.

Management

• Current GRACE score-based guidance for early invasive management has proven ineffective; novel risk stratification tools like INFLAME-MI may complement existing models.
• Tailored secondary prevention and timing of invasive management should consider inflammation-based risk assessment.

Monitoring & Follow-up

• Monitor inflammatory biomarkers and clinical parameters during early hospital admission to assess risk and guide clinical decisions.

Risks

• Overreliance on GRACE scores may lead to overestimation of risk and inappropriate management decisions.
• INFLAME-MI requires further validation before routine clinical use to avoid potential misclassification due to model overfit.

Patient & Prescribing Data

Patients with acute myocardial infarction in early hospital admission

Inflammation-focused risk scores like INFLAME-MI may improve risk stratification and guide personalized management, but require further prospective validation.

Clinical Best Practices

• Incorporate inflammatory biomarkers alongside traditional clinical parameters for early risk assessment after myocardial infarction.
• Use risk scores with good calibration and clinical utility, such as INFLAME-MI, especially in low-to-intermediate risk patients.
• Recognize limitations of existing risk scores and await further validation of novel models before widespread adoption.
• Consider complementary use of inflammation-based and comprehensive clinical risk models to optimize patient management.

References

• Sadler et al., INFLAME-MI score development and validation
• GRACE score evolution and limitations
• Role of inflammation in atherogenesis and ACS outcomes
• Altman and Bland on statistical interpretation